Login to Your Account



Financings Roundup

Tarsa Raises $28M Series B for Coveted Oral Osteoporosis Drug

By Catherine Shaffer
Staff Writer

Monday, March 19, 2012

Tarsa Therapeutics Inc.'s $28 million financing will push Ostora, its once-daily oral calcitonin tablet, through a new drug application (NDA) filing and a European marketing authorization application, as well as fund other pre-commercialization activities.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription